Comparison tool

PNC27 vs KPV side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

PNC27KPV

Share this peptide comparison

Property	PNC27	KPV
Category	Immune	Immune
Also known as	PNC-27, p53-HDM2 Disruptor Peptide, Anti-Cancer Peptide PNC-27	Lys-Pro-Val, Alpha-MSH fragment
FDA approved	No	No
Clinical status	Preclinical; reported in-vitro, ex-vivo human cancer-tissue, and animal research, with no human clinical trials reported. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Preclinical research ongoing; no human clinical-trial benefit evidence was provided Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Cancer research; tumor targeting; oncology research.	Gut inflammation, IBD, skin conditions and anti-inflammatory activity
How it works	The source describes a p53-derived binding segment engaging HDM-2/MDM2 reported at the surface of some cancer cells. It proposes that the peptide's amphipathic helix-loop-helix conformation can enter the membrane and form pores, leading to necrotic lysis rather than apoptosis. It also reports mitochondrial membrane disruption after entry. Reported selectivity is attributed to normal cells lacking membrane-associated HDM-2, but this remains preclinical evidence.	KPV is described as a short alpha-MSH-derived peptide with a proposed anti-inflammatory mechanism. In the supplied evidence, KPV uptake is linked to PepT1 transport, particularly in inflamed intestinal tissue. After cellular entry, laboratory findings associate KPV with dampened NF-kB activity and reduced production of inflammatory mediators such as TNF-alpha, IL-1beta and IL-6. The source also states that KPV does not appear to act through the classic melanocortin receptors used by alpha-MSH, so the mechanism remains a preclinical working model rather than a confirmed clinical pathway.
Typical dosing	No human dose - research compound only · Not applicable - no human use	200-500 mcg daily · 1-2x daily
Research dosing	0.3 mg/mL (nearly 100% leukemia cell killing) · Research protocols only - no human use data · IV injection in animal studies - not for human use	200-500 mcg daily · 4-8 weeks typical · Subcutaneous injection or oral capsules
Typical duration	Research protocols only - no human use data	4-8 weeks typical
Administration	-	Subcutaneous injection or oral capsules
Timing	Per research protocol With or without food (source-listed; no human-use basis supplied).	Morning, or as directed in the source context With or without food
Evidence level	Preclinical	Preclinical
Possible side effects	Limited safety information is available for this research compound. (Human safety data were not supplied.) The source reports in-vitro selectivity for cancer cells. (This is a laboratory observation, not a human safety finding.) No cytotoxicity was reported in normal fibroblasts and leukocytes. (Reported in vitro; it does not establish systemic safety.) +4 more Reported activity was temperature dependent, with 37°C described as optimal and 17°C as minimal. (Laboratory-condition observation.) No human clinical trials were reported. (Human adverse-effect frequency and severity are therefore unknown.) Systemic effects in humans are unknown. (No human clinical evidence was supplied.) Potential immunogenicity is unknown. (No human clinical evidence was supplied.)	Generally well tolerated (Reported by the source; human clinical safety evidence was not provided.) Injection-site reactions (Listed for injectable use.) Transient mild flu-like symptoms (Reported as mild and temporary in the source.) +4 more Mild gastrointestinal effects (Listed without additional severity detail.) Possible histamine release (Source advises caution for MCAS or histamine sensitivity; supporting human trial data was not provided.) Does not cause immunosuppression (Source reports this as a safety-related claim; corroborating clinical evidence was not supplied.) Cancer-history contraindication claim (Source lists this as a contraindication; independent clinical substantiation was not provided in the input.)
Research summary	The source characterizes a 2010 PNAS report by Sarafraz-Yazdi and colleagues as evidence for HDM-2 binding and cancer-cell lysis, and it mentions a separate 2010 intact-peptide lysis study. It also describes a 2022 Biomedicines publication as consistent with membrane-pore and selectivity findings in cell lines; according to the source, normal cells made to express membrane HDM-2 became susceptible. These accounts concern in-vitro, ex-vivo, and animal work. No completed human trial is reported to establish safety or anticancer benefit.	The supplied research summary places KPV in a preclinical evidence tier. It cites Dalmasso and colleagues in Gastroenterology in 2008 for PepT1-dependent uptake and reduced intestinal inflammation in experimental colitis models, including DSS and TNBS mouse models, alongside lower pro-inflammatory cytokine signals. A 2016 PMC-listed study is described as showing fewer tumors in a mouse model of colitis-associated cancer when KPV activity depended on PepT1. The source emphasizes that these are animal and in vitro findings and does not provide published randomized human trials for inflammatory bowel disease, eczema or other promoted uses.
References	Source Source +3 more Source Source Source	Source Source +1 more Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

PNC27

KPV

Category

Immune

Also known as

PNC-27, p53-HDM2 Disruptor Peptide, Anti-Cancer Peptide PNC-27

Lys-Pro-Val, Alpha-MSH fragment

FDA approved

Clinical status

Preclinical; reported in-vitro, ex-vivo human cancer-tissue, and animal research, with no human clinical trials reported.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Preclinical research ongoing; no human clinical-trial benefit evidence was provided

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Cancer research; tumor targeting; oncology research.

Gut inflammation, IBD, skin conditions and anti-inflammatory activity

How it works

The source describes a p53-derived binding segment engaging HDM-2/MDM2 reported at the surface of some cancer cells. It proposes that the peptide's amphipathic helix-loop-helix conformation can enter the membrane and form pores, leading to necrotic lysis rather than apoptosis. It also reports mitochondrial membrane disruption after entry. Reported selectivity is attributed to normal cells lacking membrane-associated HDM-2, but this remains preclinical evidence.

KPV is described as a short alpha-MSH-derived peptide with a proposed anti-inflammatory mechanism. In the supplied evidence, KPV uptake is linked to PepT1 transport, particularly in inflamed intestinal tissue. After cellular entry, laboratory findings associate KPV with dampened NF-kB activity and reduced production of inflammatory mediators such as TNF-alpha, IL-1beta and IL-6. The source also states that KPV does not appear to act through the classic melanocortin receptors used by alpha-MSH, so the mechanism remains a preclinical working model rather than a confirmed clinical pathway.

Typical dosing

No human dose - research compound only · Not applicable - no human use

200-500 mcg daily · 1-2x daily

Research dosing

0.3 mg/mL (nearly 100% leukemia cell killing) · Research protocols only - no human use data · IV injection in animal studies - not for human use

200-500 mcg daily · 4-8 weeks typical · Subcutaneous injection or oral capsules

Typical duration

Research protocols only - no human use data

4-8 weeks typical

Administration

Subcutaneous injection or oral capsules

Timing

Per research protocol

With or without food (source-listed; no human-use basis supplied).

Morning, or as directed in the source context

With or without food

Evidence level

Preclinical

Possible side effects

Limited safety information is available for this research compound. (Human safety data were not supplied.)
The source reports in-vitro selectivity for cancer cells. (This is a laboratory observation, not a human safety finding.)
No cytotoxicity was reported in normal fibroblasts and leukocytes. (Reported in vitro; it does not establish systemic safety.)

+4 more

Reported activity was temperature dependent, with 37°C described as optimal and 17°C as minimal. (Laboratory-condition observation.)
No human clinical trials were reported. (Human adverse-effect frequency and severity are therefore unknown.)
Systemic effects in humans are unknown. (No human clinical evidence was supplied.)
Potential immunogenicity is unknown. (No human clinical evidence was supplied.)

Generally well tolerated (Reported by the source; human clinical safety evidence was not provided.)
Injection-site reactions (Listed for injectable use.)
Transient mild flu-like symptoms (Reported as mild and temporary in the source.)

+4 more

Mild gastrointestinal effects (Listed without additional severity detail.)
Possible histamine release (Source advises caution for MCAS or histamine sensitivity; supporting human trial data was not provided.)
Does not cause immunosuppression (Source reports this as a safety-related claim; corroborating clinical evidence was not supplied.)
Cancer-history contraindication claim (Source lists this as a contraindication; independent clinical substantiation was not provided in the input.)

Research summary

The source characterizes a 2010 PNAS report by Sarafraz-Yazdi and colleagues as evidence for HDM-2 binding and cancer-cell lysis, and it mentions a separate 2010 intact-peptide lysis study. It also describes a 2022 Biomedicines publication as consistent with membrane-pore and selectivity findings in cell lines; according to the source, normal cells made to express membrane HDM-2 became susceptible. These accounts concern in-vitro, ex-vivo, and animal work. No completed human trial is reported to establish safety or anticancer benefit.

The supplied research summary places KPV in a preclinical evidence tier. It cites Dalmasso and colleagues in Gastroenterology in 2008 for PepT1-dependent uptake and reduced intestinal inflammation in experimental colitis models, including DSS and TNBS mouse models, alongside lower pro-inflammatory cytokine signals. A 2016 PMC-listed study is described as showing fewer tumors in a mouse model of colitis-associated cancer when KPV activity depended on PepT1. The source emphasizes that these are animal and in vitro findings and does not provide published randomized human trials for inflammatory bowel disease, eczema or other promoted uses.

References

+3 more

+1 more

Full profile